Vitamin D receptor has antiproliferative effects in pulmonary arterial hypertension, but receptor expression is downregulated ...

Two industry-sponsored studies investiaged needs of people with pulmonary hypertesion and interstitial lung disease.

California’s XOMA Royalty Corporation has announced that it now owns an economic interest in seralutinib, a Phase III asset being studied in pulmonary arterial hypertension (PAH), through its $20 ...

Seralutinib becomes XOMA Royalty’s seventh Phase 3 royalty asset, further building the late-stage pipeline beyond its six ...

Royalty Corporation now owns an economic interest in seralutinib, a Phase 3 asset being studied in pulmonary arterial hypertension ...

Pulmonary hypertension (PH), a serious lung and heart condition, elevates blood pressure in lung arteries, causing shortness ...

Winrevair lowered death or transplant risk in adults with PAH functional class 3-4 at high risk of dying; all in study may ...

Under the commercialisation agreement with Getz Healthcare, Beyond Air is set to obtain a $1m milestone payment.

The table below is a review of notable updates that occurred in November 2024 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

XOMA Royalty Corp. (XOMA), a biotechnology royalty aggregator, Monday announced that it now owns royalty and milestone interest in ...

Presentations at the 2024 Asembia Specialty Pharmacy Summit focused on reshaping specialty pharmacy while keeping patients ...

Penn Highlands Healthcare welcomes certified family nurse practitioner Eryn Thomas, FNP-C, to its medical staff.